Hemab Therapeutics Holdings, Inc.
34.40USD
-0.4150 (-1.19%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on COAG.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | -26 | -24 | -16 | -17 |
| Net Income | -24 | -23 | -12 | -15 |
| EPS (Diluted) | -$0.80 | -$23.98 | -$12.91 | -$16.18 |
Source: SEC filings (EDGAR)